

Subject: \$/Y and Biotech [C]
From: Tazia Smith <[REDACTED]>
Date: Wed, 23 Apr 2014 11:54:04 -0400
To: jeevacation@gmail.com
Cc: [REDACTED],
Paul Morris <[REDACTED]>,
Nav Gupta <[REDACTED]>,
Vinit Sahn <[REDACTED]>,
Vahe Stepanian <[REDACTED]>

Classification: Confidential

Jeffrey -

Just posting you on your biotech basket - earnings a positive catalyst reversing that downtrend in Gilead. Biogen reported this morning (bottom line miss, top-line beat), stock has come in from pre-market highs of \$310, now ~\$303 (3-day chart below).

Just a reminder that your \$Y 102.5 call is going to expire 5/1. In speaking with Nav and Vinit, they looked at lot of weaker-yen iterations but their view is vols are too low and there is an absence of catalysts to present a compelling trade at this moment to roll into; Nav will email you directly to highlight entry points on a trade when he sees one. As you know, you've got your zero-cost option on for some exposure to yen weakness.

(Embedded image moved to file: pic25012.gif) Source: Pershing, LLC and Bloomberg

(Embedded image moved to file: pic20056.gif)

Biogen - 3-day inter-day chart

(Embedded image moved to file: pic27955.gif)

(Embedded image moved to file: pic15934.gif)

Tazia Smith
Director | Key Client Partners - US

DB Securities Inc
Deutsche Asset & Wealth Management
345 Park Avenue, 10154-0004 New York, NY, USA
Tel. [REDACTED]
Fax [REDACTED]
Mobile [REDACTED]
Email [REDACTED]

(Embedded image moved to file: pic28276.gif)